Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?
, , , , , , , , oraz
06 cze 2018
O artykule
Kategoria artykułu: Review
Data publikacji: 06 cze 2018
Zakres stron: 121 - 128
Otrzymano: 07 lis 2017
Przyjęty: 12 mar 2018
DOI: https://doi.org/10.2478/raon-2018-0023
Słowa kluczowe
© 2018 Tomas Kazda, Adam Dziacky, Petr Burkon, Petr Pospisil, Marek Slavik, Zdenek Rehak, Radim Jancalek, Pavel Slampa, Ondrej Slaby, Radek Lakomy, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1

Recommendations for target definition according to EORTC, RTOG and ESTRO-ACROP
Contouring approach | Dose prescription | GTV | CTV |
---|---|---|---|
EORTC |
30 × 2.0 Gy | Resection cavity + residual T1 enhancement | GTV + 2 cm |
RTOG |
23 × 2.0 Gy | GTV1: Resection cavity + residual T1 enhancement + FLAIR abnormality (oedema) | CTV1 = GTV1 + 2 cm (the margin is 2.5 cm in cases where no oedema is presented) |
+ 7 × 2.0 Gy | GTV2: Resection cavity + residual T1 enhancement | GTV2 + 2 cm | |
ESTRO-ACROP | 30 × 2.0 Gy | Resection cavity + residual T1 enhancement + FLAIR abnormality (oedema) for secondary glioblasomas | GTV + 2 cm |